b'Source: Older Patients with Acute Myeloid Leukemia Deserve Individualized Treatment. Curr Oncol Rep. 2022 Nov;24(11):1387-1400. doi: 10.1007/s11912-022-01299-9. Epub 2022 Jun 2.22% survived to at least 24 months in this high-riskthe combination of OR2100 plus Ven is a promising population, they said. 2 candidate oral therapy for AML. 3Further, they found that the use of HMA/Ven as1de Leeuw DC, Ossenkoppele GJ, Janssen JJWM. Older Patients with a bridge to HSCT was successful in several patientsAcute Myeloid Leukemia Deserve Individualized Treatment. Curr with deeper responses who remained in remission atOncol Rep. 2022 Nov;24(11):1387-1400. doi: 10.1007/s11912-022-the end of follow-up. This regimen may represent a01299-9. Epub 2022 Jun 2.viable means of low-intensity re-induction prior to2Tenold ME, Moskoff BN, Benjamin DJ, Hoeg RT, Rosenberg AS, HSCT consolidation. Abedi M, Tuscano JM, Jonas BA. Outcomes of Adults With Relapsed/Refractory Acute Myeloid Leukemia Treated With Venetoclax Plus Otherresearchersconductedastudyevaluated aHypomethylating Agents at a Comprehensive Cancer Center. Front new HMA, OR21, which can be administered orally,Oncol. 2021 Mar 11;11:649209. doi: 10.3389/fonc.2021.649209.unlike azacytidine or decitabine which are typically3Kamachi K, Ureshino H, Watanabe T, Yoshida-Sakai N, Fukuda-Kura-administeredparenterallybecauseofdegradationhashi Y, Kawasoe K, Hoshiko T, Yamamoto Y, Kurahashi Y, Kimura by cytidine deaminase, although orally bioavailableS. Combination of a New Oral Demethylating Agent, OR2100, and Venetoclax for Treatment of Acute Myeloid Leukemia. Cancer Res forms (CC-486 and ASTX727) are available. TheyCommun. 2023 Feb 21;3(2):297-308. doi: 10.1158/2767-9764.CRC-found that OR21 plus venetoclax synergistic anti- 22-0259.leukemia effects in vitro and vivo, suggesting that 18'